| Year |
Citation |
Score |
| 2015 |
Tahata Y, Hiramatsu N, Oze T, Morishita N, Harada N, Yamada R, Yakushijin T, Mita E, Hagiwara H, Yamada Y, Ito T, Hijioka T, Inada M, Katayama K, Tamura S, et al. The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin. Journal of Gastroenterology. PMID 26223482 DOI: 10.1007/s00535-015-1105-9 |
0.476 |
|
| 2015 |
Yamada R, Hiramatsu N, Oze T, Morishita N, Harada N, Yakushijin T, Iio S, Doi Y, Yamada A, Kaneko A, Hagiwara H, Mita E, Oshita M, Itoh T, Fukui H, et al. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection. Journal of Gastroenterology. 50: 785-94. PMID 25384794 DOI: 10.1007/S00535-014-1010-7 |
0.432 |
|
| 2015 |
Oze T, Hiramatsu N, Yakushijin T, Yamada R, Harada N, Morishita N, Oshita M, Mita E, Ito T, Inui Y, Inada M, Tamura S, Yoshihara H, Imai Y, Kato M, et al. The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1. Journal of Viral Hepatitis. 22: 254-62. PMID 25081140 DOI: 10.1111/jvh.12289 |
0.463 |
|
| 2015 |
Oze T, Hiramatsu N, Yakushijin T, Yamada R, Harada N, Morishita N, Yamada A, Oshita M, Kaneko A, Suzuki K, Inui Y, Tamura S, Yoshihara H, Imai Y, Miyagi T, et al. The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1. Journal of Gastroenterology. 50: 313-22. PMID 24806033 DOI: 10.1007/S00535-014-0965-8 |
0.463 |
|
| 2014 |
Kaneko J, Sugawara Y, Yamaguchi T, Harada N, Akamatsu N, Ishizawa T, Aoki T, Sakamoto Y, Hasegawa K, Tamura S, Tanaka T, Kokudo N. Telaprevir-based triple therapy for hepatitis C null responders among living donor liver transplant recipients. Bioscience Trends. 8: 339-45. PMID 25641181 DOI: 10.5582/bst.2014.01101 |
0.473 |
|
| 2014 |
Harada N, Hiramatsu N, Oze T, Morishita N, Yamada R, Hikita H, Miyazaki M, Yakushijin T, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, Kasahara A, Oshita M, Mita E, et al. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin. Journal of Viral Hepatitis. 21: 357-65. PMID 24716638 DOI: 10.1111/jvh.12151 |
0.455 |
|
| 2014 |
Harada N, Tamura S, Sugawara Y, Togashi J, Ishizawa T, Kaneko J, Aoki T, Sakamoto Y, Hasegawa K, Tanaka T, Yamashiki N, Kokudo N. Impact of donor and recipient single nucleotide polymorphisms of IL28B rs8099917 in living donor liver transplantation for hepatitis C. Plos One. 9: e90462. PMID 24599320 DOI: 10.1371/journal.pone.0090462 |
0.451 |
|
| 2013 |
Harada N, Sugawara Y, Akamatsu N, Kaneko J, Tamura S, Aoki T, Sakamoto Y, Hasegawa K, Yamashiki N, Kokudo N. New-onset diabetes mellitus developing in Asian adult living donor liver transplant recipients: A single-center experience Journal of Hepato-Biliary-Pancreatic Sciences. 20: 634-638. DOI: 10.1007/s00534-013-0602-6 |
0.386 |
|
| 2000 |
Akahoshi K, Kondoh A, Nagaie T, Koyanagi N, Nakanishi K, Harada N, Nawata H. Preoperative staging of rectal cancer using a 7.5 MHz front-loading US probe. Gastrointestinal Endoscopy. 52: 529-34. PMID 11023575 |
0.3 |
|
| Show low-probability matches. |